Cancer screening backlogs grow as pandemic strains global care

The COVID-19 pandemic has led to a record backlog in cancer screening worldwide, with millions of routine breast, cervical, bowel and lung checks disrupted as health systems prioritised urgent COVID-19 care. The backlog is not simply a queue of postponed appointments. It represents time during which precancerous changes and undiagnosed cancers could progress without being found.

For many people, the first signs of a problem appear between routine visits. A breast lump noticed at home, abnormal bleeding or persistent changes in bowel habits need investigation regardless of whether a screening invitation has arrived. Delays in diagnostic imaging, endoscopy and pathology can turn a manageable abnormality into a more advanced and harder-to-treat disease.

Cancer services did not stop entirely. Clinicians continued to diagnose and treat symptomatic patients, while screening programmes adapted through referral triage, shortened appointment intervals and expanded telehealth. Nevertheless, repeated lockdowns, staff redeployment and infection-control measures created backlogs that normal capacity alone cannot quickly absorb.

The effects differ by programme, and the consequences depend on how quickly an abnormal result is investigated. Screening is only one step: a positive home test may require a colonoscopy, an abnormal cervical sample may need repeat testing, and a suspicious imaging finding may need a biopsy. When those follow-up steps are delayed, a backlog of routine checks can become a backlog of possible cancers.

A global interruption in early detection

Before 2020, cancer screening had become a routine part of many public health systems. Mammograms, cervical screening and bowel tests allowed clinicians to find disease before symptoms appeared, while targeted lung screening helped high-risk participants investigate nodules. The sudden suspension or reduction of non-urgent services exposed how dependent those programmes were on ordinary appointments and stable staffing.

The disruption was uneven because countries entered the pandemic with different testing coverage, staffing levels and recovery routes. Some systems briefly paused population programmes; others continued appointments under stricter infection controls. During the worst waves, people also declined or struggled to attend because of caring duties, lost income, border closures or fear of infection.

A nasal spray vaccine report highlights a related form of resilience: better ways to prevent respiratory infection can reduce illness, staff absence and service pressure, preserving appointments for people whose cancers cannot wait. Prevention and early detection work together, because fewer avoidable infections leave more clinical capacity for cancer diagnosis and treatment.

How postponed checks became backlogs

When a mammogram is moved, the appointment can often be rearranged within weeks. A bowel screening pathway may involve posting a kit, returning it through the mail, arranging a GP discussion and then booking a colonoscopy, so disruption at several points can add months. Cervical screening also relies on a sequence of sampling, laboratory analysis and, where needed, treatment and follow-up.

Staff redeployment compounded the effect. Nurses, radiographers, endoscopists and laboratory workers who normally support screening were needed in emergency departments, testing centres and vaccination clinics. Their absence created a shortage of appointments and of people able to complete every stage of a pathway. Later waves, including Omicron, renewed pressure on staff and disrupted recovery plans.

Routine demand then met a diminished supply. People who delayed care during lockdowns became eligible for investigations at the same time as programmes tried to clear missed invitations. National audits and cancer registries now show growing diagnostic workloads alongside delayed diagnoses. For clinical context on symptoms requiring assessment outside a routine programme, Urology Science provides relevant background on urological diagnostic pathways.

Why delayed investigation changes outcomes

The purpose of screening is to find a problem early enough to change the course of disease. Waiting longer for a mammogram or cervical follow-up can allow a small tumour or precancerous lesion to develop, reducing the options available when the diagnosis is finally made. For bowel cancer, the interval between a positive faecal immunochemical test and colonoscopy can influence whether abnormal cells are contained or have spread.

Backlogs also affect people already living with cancer. Diagnostic services must distinguish new cancers from treatment effects, while surgery and radiotherapy teams manage patients whose treatment has been postponed. A queue designed for routine screening can therefore compete with oncology work, creating a wider ripple through the health system rather than a contained administrative problem.

The social effects are equally serious. Delayed reassurance, financial stress from illness and caring responsibilities, and uncertainty about test results affect patients and families. The burden can fall hardest on people with insecure work, limited transport, language barriers or little access to preventive health services. In lower-income settings, interrupted pathology, imaging and follow-up can remove essential parts of cancer care altogether.

Australia’s uneven route back

Australia’s first COVID-19 wave produced fewer severe hospital admissions than in many countries, allowing screening services to reopen sooner. Yet the disruption was still substantial. Elective surgery limits and infection controls affected investigations in Melbourne during strict lockdowns, while border closures and clinic capacity constraints complicated access in Sydney and other states.

The response has been shaped by Australia’s mixed public and private system. BreastScreen Australia offers free mammography to eligible women, the National Bowel Cancer Screening Program uses mailed test kits, and cervical screening is delivered through general practitioners and family planning clinics. Medicare-supported consultations and diagnostic pathways connect screening with specialist care, although waiting times vary between states, cities and regional districts.

Local realities make a single national catch-up figure misleading. In rural and remote communities, distance, limited specialist services and transport costs can turn a simple test into a multi-day trip. Aboriginal Community Controlled Health Services and local clinics play a vital role across the Northern Territory and regional areas, but workforce shortages and cultural safety remain central to follow-up. In suburban Melbourne and Sydney, outreach events and community pharmacies can help people return unused bowel test kits.

Australian language can also blur the distinction between a routine “check-up” and diagnostic treatment. People may say a result was “clear” or that they are “due for a screen” while still needing follow-up, making it essential for public-health messaging to explain the sequence from invitation to investigation.

Catch-up meets a stretched workforce

Clearing a backlog requires more than sending new invitations. Breast imaging needs radiographers and reporting clinicians, bowel follow-up needs gastroenterologists and endoscopy teams, and cervical recall requires nurses, laboratory staff and GPs. These are also the workers needed for urgent referrals, so prioritising overdue screening without expanding capacity can delay people whose symptoms are more concerning.

Many services have added Saturday clinics, extended hours and reminder systems, but the gains are constrained by vacancies, overtime and burnout. Catch-up work must also remain clinically selective. Extra imaging or repeat testing for people outside recommended age groups or intervals can create unnecessary procedures without matching the benefit of a missed, correctly targeted check.

Because waiting-list figures change quickly, Coronavirus News Live’s contact the news desk page provides a route for readers to share verified updates and story leads. Local reporting on cancelled appointments, completed investigations and treatment waits can show where recovery is genuine rather than equating resumed activity with resolved delays.

Building resilience without losing confidence

A resilient screening system needs clearer infection plans for future outbreaks, sufficient reserve staffing and rapid communication when appointments change. Digital reminders can help people cancel, reschedule and complete home tests, while telehealth supports triage when travel is difficult. Expanded self-collection for HPV screening, used only where approved and appropriate, can also reduce barriers for people who have not previously attended a clinic.

Investment in the diagnostic chain matters as much as outreach. A breast service cannot resolve its backlog if imaging slots are available but biopsy and surgery are not; a bowel programme cannot succeed if positive kits arrive without colonoscopies. Shared planning across primary care, hospitals and pathology laboratories can match demand with capacity and prioritise investigations according to clinical risk.

Public trust must be protected alongside capacity. Messaging should explain who is eligible, what each test can and cannot detect, and how abnormal results are followed up. Clear updates through clinicians, pharmacies and community health workers are especially important in regional Australia, where residents may encounter several agencies before completing a pathway. Transparency about waits is more credible than declaring a backlog cleared on the day extra appointments begin.

Across every region, the meaningful measure of recovery is not the number of invitations reissued. It is whether precancerous changes are treated before cancer develops, whether symptomatic disease is investigated without delay, and whether no community is left carrying the hidden cost of the pandemic.